

Luca Pastorelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3741496/publications.pdf>

Version: 2024-02-01

73
papers

2,885
citations

218381

26
h-index

174990

52
g-index

77
all docs

77
docs citations

77
times ranked

5053
citing authors

#	ARTICLE	IF	CITATIONS
1	Multidimensional Prognostic Index Predicts Clinical Outcome and Mortality in Hospitalised Older Patients with Diverticular Disease. <i>Gerontology</i> , 2022, 68, 44-52.	1.4	3
2	NF- κ B pathway is involved in microscopic colitis pathogenesis. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210801.	0.4	2
3	Constrained multiple instance learning for ulcerative colitis prediction using histological images. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 224, 107012.	2.6	7
4	Impact of COVID-19 Outbreak on the Management of Patients With Severe IBD: A Domino Effect. <i>Gastroenterology</i> , 2021, 160, 2196-2197.	0.6	4
5	Interleukin 33 Triggers Early Eosinophil-Dependent Events Leading to Metaplasia in a Chronic Model of Gastritis-Prone Mice. <i>Gastroenterology</i> , 2021, 160, 302-316.e7.	0.6	38
6	Staging esophageal cancer: low EUS accuracy in T2N0 patients. <i>Endoscopy International Open</i> , 2021, 09, E313-E318.	0.9	4
7	Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. <i>Digestive and Liver Disease</i> , 2021, 53, 263-270.	0.4	23
8	Proinflammatory Interleukin-33 Induces Dichotomic Effects on Cell Proliferation in Normal Gastric Epithelium and Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5792.	1.8	6
9	Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3050-3055.	1.4	16
10	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1432-1441.	1.9	11
11	Editorial: The Dark Side of Microscopic Colitis. <i>Frontiers in Medicine</i> , 2021, 8, 809136.	1.2	1
12	Efficacy and tolerability of high and low-volume bowel preparation compared: A real-life single-blinded large-population study. <i>World Journal of Gastrointestinal Endoscopy</i> , 2021, 13, 659-672.	0.4	3
13	Low prevalence of colorectal neoplasia in microscopic colitis: A large prospective multi-center study. <i>Digestive and Liver Disease</i> , 2020, 53, 846-851.	0.4	6
14	Response to Italian IBD Patients Coping With COVID-19 Emergency: The Mitigating Role of Psychological Readiness to Engage in Self-Care. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e123-e123.	0.9	0
15	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , 2020, 69, 1213-1217.	6.1	283
16	Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey. <i>Digestive and Liver Disease</i> , 2020, 52, 1396-1402.	0.4	47
17	Hold the Foam: Why Topical Budesonide Remains Relevant for IBD Therapy. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3066-3068.	1.1	2
18	Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. <i>Journal of Molecular Medicine</i> , 2020, 98, 595-612.	1.7	31

#	ARTICLE	IF	CITATIONS
19	Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 793-796.	0.9	45
20	Proteomic insights on the metabolism in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 696-705.	1.4	6
21	Terminal ileum ileoscopy and histology in patients undergoing high-definition colonoscopy with virtual chromoendoscopy for chronic nonbloody diarrhea: A prospective, multicenter study. <i>United European Gastroenterology Journal</i> , 2019, 7, 974-981.	1.6	7
22	A rare case of angina bullosa hemorrhagica of the esophagus. <i>Endoscopy</i> , 2019, 51, E408-E409.	1.0	1
23	Editorial: the increasing burden of microscopic colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 228-229.	1.9	3
24	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36
25	Major duodenal papilla prolapse in Cronkhite’s “Canada syndrome. <i>Endoscopy</i> , 2019, 51, E81-E82.	1.0	1
26	Use, effectiveness and tolerability of budesonide “MMX in ulcerative colitis: A real-life experience. <i>United European Gastroenterology Journal</i> , 2019, 7, 1164-1170.	1.6	9
27	Bowel Sonoelastography in Patients with Crohn’s Disease: A Systematic Review. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 297-302.	0.7	21
28	Editorial: Intestinal Inflammation. <i>Frontiers in Medicine</i> , 2018, 5, 318.	1.2	0
29	IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9362-E9370.	3.3	110
30	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
31	Thulium laser in interventional endoscopy: animal and human studies. <i>Endoscopy</i> , 2017, 49, 365-370.	1.0	20
32	Surveillance strategies for colitis-associated cancer: state of the art and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 427-437.	1.4	1
33	Interleukin-37: A Peacekeeper at the Intestinal Borders. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1103-1106.	1.1	0
34	Contribution of Extracellular Matrix and Signal Mechanotransduction to Epithelial Cell Damage in Inflammatory Bowel Disease Patients: A Proteomic Study. <i>Proteomics</i> , 2017, 17, 1700164.	1.3	39
35	MMX [®] technology and its applications in gastrointestinal diseases. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 545-552.	1.4	24
36	Ex vivo experimental study on the Thulium laser system: new horizons for interventional endoscopy (with videos). <i>Endoscopy International Open</i> , 2017, 05, E410-E415.	0.9	12

#	ARTICLE	IF	CITATIONS
37	A consumer's guide for probiotics: 10 golden rules for a correct use. Digestive and Liver Disease, 2017, 49, 1177-1184.	0.4	45
38	Endoscopic full-thickness resection for T1 early rectal cancer: a case series and video report. Endoscopy International Open, 2017, 05, E1081-E1086.	0.9	17
39	Small-bowel capsule endoscopy with panoramic view: results of the first multicenter, observational study (with videos). Gastrointestinal Endoscopy, 2017, 85, 401-408.e2.	0.5	27
40	Biomarkers and Microscopic Colitis: An Unmet Need in Clinical Practice. Frontiers in Medicine, 2017, 4, 54.	1.2	25
41	Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-12.	0.8	25
42	Effect of proton pump inhibitors on magnesium balance: is there a link to cardiovascular risk?. Magnesium Research, 2016, 29, 1-10.	0.4	3
43	In-vivo Axial-strain Sonoelastography Helps Distinguish Acutely-inflamed from Fibrotic Terminal Ileum Strictures in Patients with Crohn's Disease: Preliminary Results. Ultrasound in Medicine and Biology, 2016, 42, 855-863.	0.7	32
44	Over-the-scope clip-assisted endoscopic full-thickness resection after incomplete resection of rectal adenocarcinoma. Endoscopy, 2016, 48, E59-E60.	1.0	9
45	Microscopic Colitis. Inflammatory Bowel Diseases, 2016, 22, 450-458.	0.9	78
46	Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. Inflammatory Bowel Diseases, 2016, 22, 2977-2987.	0.9	24
47	IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis. American Journal of Pathology, 2016, 186, 885-898.	1.9	62
48	Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World Journal of Gastroenterology, 2015, 21, 21.	1.4	160
49	Procoagulatory State in Inflammatory Bowel Diseases Is Promoted by Impaired Intestinal Barrier Function. Gastroenterology Research and Practice, 2015, 2015, 1-10.	0.7	20
50	Advances in endoscopic imaging in ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1393-1405.	1.4	5
51	IL-33 activates tumor stroma to promote intestinal polyposis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2487-96.	3.3	141
52	Mo1588 The New 360° Panoramic-Viewing Capsule Endoscopy System: Results of the First Multicenter, Observational, Study. Gastrointestinal Endoscopy, 2015, 81, AB476.	0.5	1
53	Use of an over-the-scope clip for endoscopic sealing of anastomotic dehiscence after anterior resection for rectal cancer. Endoscopy, 2015, 47, E278-E279.	1.0	0
54	Extensive small-bowel Crohn's disease detected by the newly introduced 360° panoramic viewing capsule endoscopy system. Endoscopy, 2014, 46, E353-E354.	1.0	9

#	ARTICLE	IF	CITATIONS
55	Microscopic Colitis and Colorectal Neoplastic Lesion Rate in Chronic Nonbloody Diarrhea. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 882-891.	0.9	34
56	Tu1535 Microscopic Colitis and Colorectal Neoplastic Lesions in Patients With Chronic Non-Bloody Diarrhea: a Prospective, Multicenter Study. <i>Gastrointestinal Endoscopy</i> , 2014, 79, AB575.	0.5	0
57	Neurological disorders and inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2014, 20, 8764-82.	1.4	44
58	The Role of IL-33 in Gut Mucosal Inflammation. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	1.4	68
59	Central Role of the Gut Epithelial Barrier in the Pathogenesis of Chronic Intestinal Inflammation: Lessons Learned from Animal Models and Human Genetics. <i>Frontiers in Immunology</i> , 2013, 4, 280.	2.2	337
60	Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2013, 8, e62144.	1.1	75
61	Probiotic Bacteria Regulate Intestinal Epithelial Permeability in Experimental Ileitis by a TNF-Dependent Mechanism. <i>PLoS ONE</i> , 2012, 7, e42067.	1.1	97
62	Anti-TNF Therapy Improves Stored Body Iron Serum Markers in Inflammatory Bowel Disease Patients. <i>Gastroenterology</i> , 2011, 140, S-278.	0.6	0
63	Spontaneous, Immune-Mediated Gastric Inflammation in SAMP1/YitFc Mice, a Model of Crohn's-Like Gastritis. <i>Gastroenterology</i> , 2011, 141, 1709-1719.	0.6	15
64	CS07-4. Gastritis and potent gastric epithelial alterations in mice following exogenous administration of recombinant IL-33. <i>Cytokine</i> , 2011, 56, 52.	1.4	0
65	SAMP1/YitFc mouse strain: A spontaneous model of Crohn's disease-like ileitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2566-2584.	0.9	159
66	Circulating OPG levels are reduced following infliximab treatment and correlate with CRP levels. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E59-E60.	0.9	4
67	Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 311-323.	1.4	42
68	Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8017-8022.	3.3	373
69	Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 291-300.	0.6	21
70	PS2-12 Mechanisms of probiotic regulation of intestinal permeability in experimental Crohn's Disease (CD). <i>Cytokine</i> , 2010, 52, 52.	1.4	0
71	Emerging drugs for the treatment of ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 505-521.	1.0	24
72	Do antibodies have a role in IBD pathogenesis?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S95-S96.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Oral, colonicâ€release lowâ€molecularâ€weight heparin: an initial open study of Parnaparinâ€MMX for the treatment of mildâ€toâ€moderate leftâ€sided ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 581-588.	1.9	40